Carlos Carillo - SAB Biotherapeutics Senior Affairs
| SABS Stock | USD 3.03 0.10 3.19% |
Executive
Carlos Carillo is Senior Affairs of SAB Biotherapeutics
| Address | 777 W 41st St., Miami Beach, FL, United States, 33140 |
| Phone | 605 679 6980 |
| Web | https://www.sabbiotherapeutics.com |
SAB Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7473) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, SAB Biotherapeutics' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 2.7 M in 2024, whereas Total Assets are likely to drop slightly above 63.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| James Wang | Virax Biolabs Group | N/A | |
| Christopher Dinsmore | Third Harmonic Bio | 57 | |
| FACC FAHA | Cadrenal Therapeutics, Common | 66 | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Dennis Dean | Third Harmonic Bio | N/A | |
| Russell MBA | Processa Pharmaceuticals | 65 | |
| Khullani JD | Cardio Diagnostics Holdings | 40 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Ommer Chohan | Third Harmonic Bio | N/A | |
| Steven Sweeney | Third Harmonic Bio | N/A | |
| Esq JD | Cardio Diagnostics Holdings | 60 | |
| JD Esq | Processa Pharmaceuticals | 50 | |
| James Stanker | Processa Pharmaceuticals | 66 | |
| Christopher Murphy | Third Harmonic Bio | 40 | |
| Jennifer Dittman | Third Harmonic Bio | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 |
SAB Biotherapeutics Leadership Team
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Ex CFO | ||
| MD MBA, Executive Officer | ||
| Mark Conley, Interim Officer | ||
| Eddie Sullivan, President, CoFounder | ||
| Carlos Carillo, Senior Affairs | ||
| Christoph MBA, Executive COO | ||
| Michael King, EVP CFO | ||
| Samuel Reich, Executive Chairman | ||
| Christine MBA, CoFounder Director | ||
| Edward DVM, CoFounder Observer |
SAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SAB Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | 3.01 M | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 34.24 % | ||||
| Number Of Shares Shorted | 58.76 K | ||||
| Price To Book | 0.78 X | ||||
| Price To Sales | 19.10 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.